MA5-12748

antibody from Invitrogen Antibodies

Targeting: DNAJA1 dj-2, hdj-2, HSJ2, HSPF4, NEDD7

Provider product page for MA5-12748

Western blot

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [32]
Comments [0]
Validations
Western blot [2]
Immunohistochemistry [1]
Other assay [5]

Submit

Product number: MA5-12748 - Provider product page
Provider: Invitrogen Antibodies
Product name: HDJ2 Monoclonal Antibody (KA2A5.6)
Antibody type: Monoclonal
Antigen: Purifed from natural sources
Description: MA5-12748 targets HDJ-2/DNAJ in FACS, IF, IHC (P), IP, and WB applications and shows reactivity with Bacteria, Hamster, Human, mouse, Non-human primate, Porcine, Rabbit, and Rat samples.
Antibody clone number: KA2A5.6
Concentration: 0.2 mg/mL

DNAJA1 protein structure - MA5-12748 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of HDJ2 using a monoclonal antibody (Product # MA5-12748).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of HDJ2 using a monoclonal antibody (Product # MA5-12748).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of HDJ2 using a monoclonal antibody (Product # MA5-12748).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 Generation of forebrain neuron-specific FT knockout mice. A Schematic representation of the 3-step breeding strategy to generate APP/PS1 mice harboring homozygous FT knockout in forebrain neurons (APP/PS1/FTnKO) and littermate controls. B Representative immunoblot images of FT-beta and HDJ-2, a well-known farnesylated protein that is widely used as a marker for farnesylation, in cortical, hippocampal, cerebellar tissue homogenates of WT and FTnKO mice at 3 and 6 months of age. Unfarnesylated HDJ-2 band is detected in the forebrain region (cortex and hippocampus), but not in the cerebellum, of FTnKO mice at 3 months, and the level is elevated at 6 months, confirming both brain region- and age-dependent deletion of FT. C , D Immunoblot analysis of representative small GTPases in membrane (M) and cytosolic (C) fractions of cortical tissue lysates of FTnKO mice compared with WT controls (n = 5/genotype). Membrane-associated FT substrates, farnesylated H-Ras and Rheb, are reduced significantly or trending reduction in FTnKO compared with WT controls, whereas membrane levels of GGT substrate RhoA are not affected, confirming the specificity of FT deletion. E Representative immunoblot images of HDJ-2 in cortical tissue homogenates of APP/PS1 and APP/PS1/FTnKO mice at 9-10 months of age. F , G Immunoblot analysis of representative small GTPases in membrane (M) and cytosolic (C) fractions of cortical tissue lysates from APP/PS1 and APP/PS1/FTnKO mice at 9-10 months of age (n =

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5. Apoptotic sensitization to statin therapy by ABL allosteric inhibitors requires inhibition of protein prenylation (A) Cell viability of PC9 GR4 cells treated singly or with the combination of 5 muM ABL001 and 1 muM simvastatin supplemented with 500 muM MVA, 10 muM FPP, or 10 muM GGPP for 72 h (n = 3). Data are the mean +- SEM. (B) Immunoblots of unprenylated RAP1A, HDJ-2, and beta-tubulin in PC9 GR4 cells treated for 24 h with 5 muM ABL001 and 1 muM simvastatin supplemented with 500 muM MVA, 10 muM FPP (farnesylation metabolite), or 10 muM GGPP (geranylgeranylation metabolite). Simvastatin caused a mobility shift of HDJ-2 (slower, migrating unprenylated form) and induced the appearance of unprenylated RAP1A. Prenylation alterations were rescued with the indicated metabolites for each pathway (n = 3). (C) Cell viability of PC9 GR4 cells treated with 5 muM ABL001 and 1 muM simvastatin, 500 muM MVA, 5 muM GGTI-298 (GGT inhibitor), and 12.5 muM FTI-277 (FT inhibitor) for 72 h (n = 3). Data are the mean +- SEM. (D) Immunoblots of unprenylated RAP1A, HDJ-2, and beta-tubulin in PC9 GR4 cells treated for 24 h with 5 muM ABL001 and 1 muM simvastatin supplemented with 500 muM MVA, 5 muM GGTI-298, and 12.5 muM FTI-277 (n = 3). (E) Mitochondrial basal respiration, maximal respiration, and ATP production as measured by Seahorse XF Analyzer's Mito Stress Test for PC9 GR4 cells treated singly or with indicated combinations of 2.5 muM ABL001, 1 muM simvastatin, 500 muM MVA, 5 muM G